Despite the demonstrated efficacy and broad applicability of checkpoint blockade, the mechanisms by which it exerts its antitumor effects are incompletely understood. A recent article in Nature Medicine describes an ex vivo platform for assessing early responses to checkpoint blockade and the properties of tumor immune contexture in correlation to clinical responses.

Original languageEnglish
Pages (from-to)1187-1189
Number of pages3
JournalCancer Cell
Issue number9
StatePublished - 13 Sep 2021


Dive into the research topics of 'Tumor organoid-originated biomarkers predict immune response to PD-1 blockade'. Together they form a unique fingerprint.

Cite this